Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2094]

ASCO 2012 Drug Development Research Professorship

Dr Alex Adjei - Roswell Park Cancer Institute, Las Vegas, USA

ASCO 2012 Drug Development Research Professorship ( Dr Alex Adjei - Roswell Park Cancer Institute, Las Vegas, USA )

Effects of panitumumab against oesophageal-gastro cancer and carcinomas

Dr Tom Waddell – Royal Marsden Hospital, Sutton, UK

Effects of panitumumab against oesophageal-gastro cancer and carcinomas ( Dr Tom Waddell – Royal Marsden Hospital, Sutton, UK )

Routine molecular testing of non-small cell lung cancers in community settings

Dr Thomas Zander - University Hospital Cologne, Germany

Routine molecular testing of non-small cell lung cancers in community settings ( Dr Thomas Zander - University Hospital Cologne, Germany )

Current treatment practices in metastatic castration resistant prostate cancer

Prof Joachim Bellmunt, Prof Nicolas Mottet, Prof Noel Clarke, Prof Alfredo...

Current treatment practices in metastatic castration resistant prostate cancer ( Prof Joachim Bellmunt, Prof Nicolas Mottet, Prof Noel Clarke, Prof Alfredo Berruti )

Prognostic biomarkers and next generation genomic sequencing

Prof Stefan Pfister – Cancer Research Centre, Heidelberg, Germany

Prognostic biomarkers and next generation genomic sequencing ( Prof Stefan Pfister – Cancer Research Centre, Heidelberg, Germany )

Primary and secondary resistance in colorectal cancer

Dr Silvia Marsoni – The Institute for Cancer Research, Candiolo, Italy

Primary and secondary resistance in colorectal cancer ( Dr Silvia Marsoni – The Institute for Cancer Research, Candiolo, Italy )

Highlights and goals of IMPAKT 2012

Prof Martine Piccart – Jules Bordet Institute, Brussels, Belgium

Highlights and goals of IMPAKT 2012 ( Prof Martine Piccart – Jules Bordet Institute, Brussels, Belgium )

Molecularly characterising triple negative breast cancer

Prof Jorge Reis-Filho – Jules Bordet Institute, Brussels, Belgium

Molecularly characterising triple negative breast cancer ( Prof Jorge Reis-Filho – Jules Bordet Institute, Brussels, Belgium )

Neoadjuvant therapy and PCR through chemotherapy prior to surgery

Dr Michail Ignatiadis – Jules Bordet Institute, Brussels, Belgium

Neoadjuvant therapy and PCR through chemotherapy prior to surgery ( Dr Michail Ignatiadis – Jules Bordet Institute, Brussels, Belgium )

Overcoming drug resistance and targeting critical pathways

Dr Larry Norton – Memorial Sloan-Kettering Cancer Center, New York, USA

Overcoming drug resistance and targeting critical pathways ( Dr Larry Norton – Memorial Sloan-Kettering Cancer Center, New York, USA )

Heterogeneity of tumours and the challenges of biomarker development

Prof Giuseppe Curigliano – European Institute of Oncology, Milan, Italy

Heterogeneity of tumours and the challenges of biomarker development ( Prof Giuseppe Curigliano – European Institute of Oncology, Milan, Italy )

Targeting the PI3K/mTOR pathway

Dr Lewis Cantley – Dana-Farber Cancer Institute, Boston, USA

Targeting the PI3K/mTOR pathway ( Dr Lewis Cantley – Dana-Farber Cancer Institute, Boston, USA )

More from ecancer